1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Migraine - Pipeline Review, H2 2020, provides an overview of the Migraine (Central Nervous System) pipeline landscape.
Migraine is a disorder characterized by repeated attacks of severe headache. A migraine headache causes throbbing or pulsating pain, usually on only one side of the head. These headaches are often associated with nausea, vomiting, and extreme sensitivity to light and sound. Symptoms include problems speaking, tingling in face, arms, and shoulders, pain behind one of the eyes and pain that gets worse with routine physical activity.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Migraine - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Migraine (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Migraine (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Migraine and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 8, 18, 12, 1, 32, 6 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 2 and 3 molecules, respectively.
Migraine (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Migraine (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Migraine (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Migraine (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Migraine (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Migraine (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Migraine (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Migraine (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
IntroductionMigraine - Overview
Migraine - Therapeutics Development
Migraine - Therapeutics Assessment
Migraine - Companies Involved in Therapeutics Development
Migraine - Drug Profiles
Migraine - Dormant Projects
Migraine - Discontinued Products
Migraine - Product Development Milestones
Appendix
List of Tables
- Number of Products under Development for Migraine, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Migraine - Pipeline by 4P Therapeutics LLC, H2 2020
- Migraine - Pipeline by Acadia Pharmaceuticals Inc, H2 2020
- Migraine - Pipeline by Achelios Therapeutics Inc, H2 2020
- Migraine - Pipeline by Acorda Therapeutics Inc, H2 2020
- Migraine - Pipeline by AgoneX Biopharmaceuticals Inc, H2 2020
- Migraine - Pipeline by Allergan Ltd, H2 2020
- Migraine - Pipeline by Allodynic Therapeutics LLC, H2 2020
- Migraine - Pipeline by Amgen Inc, H2 2020
- Migraine - Pipeline by AOBiome LLC, H2 2020
- Migraine - Pipeline by Aptarion biotech AG, H2 2020
- Migraine - Pipeline by Asarina Pharma AB, H2 2020
- Migraine - Pipeline by Assertio Therapeutics Inc, H2 2020
- Migraine - Pipeline by Astrocyte Pharmaceuticals Inc, H2 2020
- Migraine - Pipeline by Avanir Pharmaceuticals Inc, H2 2020
- Migraine - Pipeline by Axsome Therapeutics Inc, H2 2020
- Migraine - Pipeline by Better Life Pharmaceuticals Inc, H2 2020
- Migraine - Pipeline by NeuroPharm Inc, H2 2020
- Migraine - Pipeline by NutriBand Inc, H2 2020
- Migraine - Pipeline by OWP Pharmaceuticals Inc, H2 2020
- Migraine - Pipeline by Panaxia Pharmaceutical Industries Ltd, H2 2020
- Migraine - Pipeline by Pharmaleads SA, H2 2020
- Migraine - Pipeline by Pharmnovo AB, H2 2020
- Migraine - Pipeline by Pherin Pharmaceuticals Inc, H2 2020
- Migraine - Pipeline by Promius Pharma LLC, H2 2020
- Migraine - Pipeline by Pulmatrix Inc, H2 2020
- Migraine - Dormant Projects, H2 2020
- Migraine - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Migraine, H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 4P Therapeutics LLC
- Acadia Pharmaceuticals Inc
- Achelios Therapeutics Inc
- Acorda Therapeutics Inc
- AgoneX Biopharmaceuticals Inc
- Allergan Ltd
- Allodynic Therapeutics LLC
- Amgen Inc
- AOBiome LLC
- Aptarion biotech AG
- Asarina Pharma AB
- Assertio Therapeutics Inc
- Astrocyte Pharmaceuticals Inc
- Avanir Pharmaceuticals Inc
- Axsome Therapeutics Inc
- Better Life Pharmaceuticals Inc
- Biogen Inc
- Biohaven Pharmaceutical Holding Company Ltd
- Blackthorn Therapeutics Inc
- Cerecin Inc
- Charleston Laboratories Inc
- Citragen Pharmaceuticals Inc
- Corium Inc
- Crossject SA
- Curatis AG
- CURx Pharmaceuticals Inc
- DelNova Inc
- Eli Lilly and Co
- Epalex Corp
- Exxel Pharma Inc
- H. Lundbeck AS
- Impel NeuroPharma Inc
- InKemia IUCT Group SA
- InStar Technologies AS
- IntelGenx Corp
- Invisio Ltd
- Ionis Pharmaceuticals Inc
- Kissei Pharmaceutical Co Ltd
- Klaria Pharma Holding AB
- Lateral Pharma Pty Ltd
- Living Cell Technologies Ltd
- MannKind Corp
- Medytox Inc
- Merck & Co Inc
- NAL Pharmaceuticals Ltd
- NeurAxon Pharma Inc
- NeuroPharm Inc
- NutriBand Inc
- OWP Pharmaceuticals Inc
- Panaxia Pharmaceutical Industries Ltd
- Pharmaleads SA
- Pharmnovo AB
- Pherin Pharmaceuticals Inc
- Promius Pharma LLC
- Pulmatrix Inc
- Qingdao Chia Tai Haier Pharmaceutical Co Ltd
- RAFT Pharmaceuticals
- Revance Therapeutics Inc
- Satsuma Pharmaceuticals Inc
- Seurat Therapeutics Inc
- Shanghai Junshi Bioscience Co Ltd
- Shin Nippon Biomedical Laboratories Ltd
- Sorrento Therapeutics Inc
- Sosei Heptares
- Suda Pharmaceuticals Ltd
- Teva Pharmaceutical Industries Ltd
- Trevena Inc
- Trigemina Inc
- TrioxBio Inc
- United Neuroscience Ltd
- Xenon Pharmaceuticals Inc
- Xoc Pharmaceuticals Inc
- Zosano Pharma Corp
